GSK plc receives positive opinion from the European Medicines Agency’s (EMA) CHMP to expand the indication for its RSV vaccine, Arexvy, to include all adults aged 18 and older. Final decision expected in February 2026, potentially broadening access beyond current approvals. Arexvy was the first RSV vaccine approved in Europe for adults 60+ and those 50-59 at increased risk of RSV disease. RSV affects an estimated 64 million people globally annually, leading to severe illness and hospitalization. GSK seeks expanded indications for its RSV vaccine in other countries like the US and Japan.

Read more at Nasdaq: GSK’s Arexvy RSV Vaccine Recommended For Expanded Use In Adults 18+ By EMA Committee